Clinical trials: Complete Response
PTCL Patients Who Achieved Complete Response From Frontline Treatment
An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL
To evaluate the efficacy and safety of Selinexor maintenance therapy in PTCL patients who achieved complete response from frontline treatment, and to analyze the relationship between gene mutation in PTCL and disease prognosis…
- Trial name
- NCT05822050
- Testing
- Selinexor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Triple Negative Breast Cancer
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery.
- Trial name
- NCT07066189
- Testing
- Exercise and Medical Nutrition
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Yale University
B-cell Acute Lymphoblastic Leukemia
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic…
- Trial name
- NCT06608732
- Testing
- Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Central Nervous System Lymphoma
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment…
- Trial name
- NCT06175000
- Testing
- Cognitive Assessment, Obinutuzumab, Quality of Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Providence Health & Services
Pathologic Complete Response
Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma
Background：Neoadjuvant chemoimmunotherapy (NACI) shows promise in oral squamous cell carcinoma (OSCC), but reliable noninvasive biomarkers for predicting pathologic complete response (pCR) remain scarce.
- Trial name
- NCT06854107
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Zilong Yuan
Rectal Cancer, Chemoradiotherapy
Non-OpeRative MANagement of Rectal Cancer Patients
This study is a single-center, open, prospective, single-treatment trial (pilot study). This study aims to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for 4 months after non-surgical treatment…
- Conditions
- Rectal Cancer, Chemoradiotherapy, Watch & Wait
- Trial name
- NORMANDY (NCT04696757)
- Testing
- Capecitabine
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Kangbuk Samsung Hospital
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
- Trial name
- TAGVEN (NCT07007052)
- Testing
- Venetoclax, Tagraxofusp
- Where
- 34 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda
Lupus Nephritis
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
- Trial name
- NCT05268289
- Testing
- Iptacopan (part 1), Iptacopan (part 2)
- Where
- 74 sites in United States, Argentina and 17 more
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Hodgkin Lymphoma
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
This trial investigates the efficacy and safety of the drug tislelizumab in combination with chemotherapy as a treatment for patients with R/R HL.
- Trial name
- HOVON164HL (NCT05502250)
- Testing
- gemcitabine, cisplatin and tislelizumab
- Where
- 15 sites in Belgium, Denmark and 1 more
- Volunteers
- 75 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Some patients with antibody-mediated autoimmune hematological diseases (warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (cAIHA) and immune thrombocytopenia (ITP)) shows no or only minor and transient response to…
- Trial name
- Ixa-Cyto (NCT03965624)
- Testing
- Ninlaro
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06498635
- Testing
- Biospecimen Collection, Computed Tomography, Durvalumab
- Where
- 281 sites in United States
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR.
- Trial name
- NCT07573397
- Volunteers
- 88 people
- Sponsor
- Fudan University